Hypercholesterolemia News and Research

RSS
Hypercholesterolemia is a condition characterized by very high levels of cholesterol in the blood. Cholesterol is a waxy, fat-like substance that is produced in the body and obtained from foods that come from animals (particularly egg yolks, meat, poultry, fish, and dairy products). The body needs this substance to build cell membranes, make certain hormones, and produce compounds that aid in fat digestion. Too much cholesterol, however, increases a person's risk of developing heart disease.

People with hypercholesterolemia have a high risk of developing a form of heart disease called coronary artery disease. This condition occurs when excess cholesterol in the bloodstream is deposited in the walls of blood vessels, particularly in the arteries that supply blood to the heart (coronary arteries). The abnormal buildup of cholesterol forms clumps (plaque) that narrow and harden artery walls. As the clumps get bigger, they can clog the arteries and restrict the flow of blood to the heart. The buildup of plaque in coronary arteries causes a form of chest pain called angina and greatly increases a person's risk of having a heart attack.

Inherited forms of hypercholesterolemia can also cause health problems related to the buildup of excess cholesterol in other tissues. If cholesterol accumulates in tendons, it causes characteristic growths called tendon xanthomas. These growths most often affect the Achilles tendons and tendons in the hands and fingers. Yellowish cholesterol deposits under the skin of the eyelids are known as xanthelasmata. Cholesterol can also accumulate at the edges of the clear, front surface of the eye (the cornea), leading to a gray-colored ring called an arcus cornealis.
Study shows why co-morbid conditions can result in impaired vision

Study shows why co-morbid conditions can result in impaired vision

New paper documents discovery of novel lipids, including MC3

New paper documents discovery of novel lipids, including MC3

FDA provides Orphan Drug Designation to Alnylam’s ALN-TTR02

FDA provides Orphan Drug Designation to Alnylam’s ALN-TTR02

Alnylam announces results from ALN-VSP Phase I study on liver cancers

Alnylam announces results from ALN-VSP Phase I study on liver cancers

Top-line results from Alnylam’s ALN-RSV01 Phase IIb trial on RSV infection

Top-line results from Alnylam’s ALN-RSV01 Phase IIb trial on RSV infection

FDA accepts NDA filing for KYNAMRO to treat HoFH

FDA accepts NDA filing for KYNAMRO to treat HoFH

Positive results from Sanofi and Regeneron’s SAR236553/REGN727 Phase 2 trial on heFH

Positive results from Sanofi and Regeneron’s SAR236553/REGN727 Phase 2 trial on heFH

Mylan introduces Atorvastatin Calcium in France, Belgium, UK, Ireland and the Netherlands

Mylan introduces Atorvastatin Calcium in France, Belgium, UK, Ireland and the Netherlands

Final results from Alnylam’s ALN-TTR01 Phase I trial on TTR-mediated amyloidosis

Final results from Alnylam’s ALN-TTR01 Phase I trial on TTR-mediated amyloidosis

Bayer Yakuhin, Santen enter co-promotion agreement for EYLEA Injection in Japan

Bayer Yakuhin, Santen enter co-promotion agreement for EYLEA Injection in Japan

Alnylam first quarter revenues decrease to $20.6 million

Alnylam first quarter revenues decrease to $20.6 million

FDA approves Novartis’ Afinitor for treatment of renal angiomyolipomas and TSC

FDA approves Novartis’ Afinitor for treatment of renal angiomyolipomas and TSC

Positive results from Alnylam’s ALN-PCS Phase I trial on severe hypercholesterolemia

Positive results from Alnylam’s ALN-PCS Phase I trial on severe hypercholesterolemia

Mylan receives final FDA approval for generic Lescol Capsules ANDA

Mylan receives final FDA approval for generic Lescol Capsules ANDA

Experimental drugs from Sanofi and Regenron cut cholesterol in a new way

Experimental drugs from Sanofi and Regenron cut cholesterol in a new way

SAR236553/REGN727 antibody reduces LDL by up to 72% in patients

SAR236553/REGN727 antibody reduces LDL by up to 72% in patients

Positive results from Amgen's AMG 145 Phase 1b study on patients with LDL-C

Positive results from Amgen's AMG 145 Phase 1b study on patients with LDL-C

New cholesterol lowering drugs on the horizon

New cholesterol lowering drugs on the horizon

Alnylam commences dosing in ALN-TTR02 Phase I clinical trial for TTR-mediated amyloidosis

Alnylam commences dosing in ALN-TTR02 Phase I clinical trial for TTR-mediated amyloidosis

Alnylam commences underwritten public offering of 7,000,000 shares of common stock

Alnylam commences underwritten public offering of 7,000,000 shares of common stock

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.